INH1 - C18H16N2OS - Bertin Bioreagent

Confirm delete?

INH1

Zoom

Cat No: 29015

Biochemicals - More Biochemicals

INH1 is an inhibitor of the interaction between the oncogene high expression in cancer 1 (Hec1) and its regulator, the serine/threonine kinase Nek2.{48794} It binds to Hec1 and reduces Nek2 protein levels in HeLa cells when used at a concentration of ...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

N-[4-(2,4-dimethylphenyl)-2-thiazolyl]-benzamide

Correlated keywords:

1780260-01-6 INH 1 Hec Nek 2 MDAMB468 MDAMB MB468 SKBR3 SKBR BR3 MDAMB361 MB361 ZR751 751 ZR75 HBL100 MDAMB435 MB435 Hs578T MCF10A MDAMB231 MB23 IBT13131

Product Overview:
INH1 is an inhibitor of the interaction between the oncogene high expression in cancer 1 (Hec1) and its regulator, the serine/threonine kinase Nek2.{48794} It binds to Hec1 and reduces Nek2 protein levels in HeLa cells when used at a concentration of 25 µM. INH1 inhibits the growth of MDA-MB-468, SK-BR-3, T47D, MDA-MB-361, ZR-75-1, HBL-100, MDA-MB-435, and Hs 578T breast cancer cells (GI50s = 10.5-20.5 µM). It inhibits migration of MDA-MB-231 cells in a transwell migration assay (IC50 = 176 nM).{48795} INH1 (50 and 100 mg/kg) reduces tumor growth in an MDA-MB-468 mouse xenograft model.{48794}

Size	5 mg
Shipping	dry ice
CAS Number	313553-47-8
Molecular Formula	C₁₈H₁₆N₂OS
SMILES	O=C(C1=CC=CC=C1)NC2=NC(C3=CC=C(C)C=C3C)=CS2
Molecular Weight	308,4
Formulation	A crystalline solid
Purity	≥98%
Custom Code	2934.10
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.